Youn Joo Lee1, In Kyung Youn2, Sung Hun Kim3, Bong Joo Kang2, Woo-Chan Park4, Ahwon Lee5. 1. Department of Radiology, St. Mary's Hospital Daejeon, Republic of Korea. 2. Seoul St. Mary's Hospital, The Catholic University of Korea, Republic of Korea. 3. Seoul St. Mary's Hospital, The Catholic University of Korea, Republic of Korea. Electronic address: rad-ksh@catholic.ac.kr. 4. Department of General Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Republic of Korea. 5. Department of Hospital Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Republic of Korea.
Abstract
PURPOSE: We aimed to investigate the magnetic resonance imaging (MRI) features and clinicopathologic factors with recurrence of triple-negative breast cancer (TNBC). PATIENTS AND METHODS: We identified 281 patients with 288 surgically confirmed TNBC lesions who underwent pretreatment MRI between 2009 and 2015. The presence of intratumoral high signal on T2-weighted images, high-signal rim on diffusion-weighted images (DWI), and rim enhancement on the dynamic contrast-enhanced MRI and clinicopathological data were collected. Cox proportional analysis was performed. RESULTS: Of the 288 lesions, 36 (12.5%) recurred after a median follow-up of 18 months (range, 3.6-68.3 months). Rim enhancement (hazard ratio [HR] = 3.15; 95% confidence interval [CI] = 1.01, 9.88; p = .048), and lymphovascular invasion (HR = 2.73, 95% CI = 1.20, 6.23; p = .016) were independently associated with disease recurrence. While fibroglandular volume, background parenchymal enhancement, intratumoral T2 high signal, and high-signal rim on DWI, were not found to be risk factors for recurrence. CONCLUSION: Pretreatment MRI features may help predict a high risk of recurrence in patients with TNBC.
PURPOSE: We aimed to investigate the magnetic resonance imaging (MRI) features and clinicopathologic factors with recurrence of triple-negative breast cancer (TNBC). PATIENTS AND METHODS: We identified 281 patients with 288 surgically confirmed TNBC lesions who underwent pretreatment MRI between 2009 and 2015. The presence of intratumoral high signal on T2-weighted images, high-signal rim on diffusion-weighted images (DWI), and rim enhancement on the dynamic contrast-enhanced MRI and clinicopathological data were collected. Cox proportional analysis was performed. RESULTS: Of the 288 lesions, 36 (12.5%) recurred after a median follow-up of 18 months (range, 3.6-68.3 months). Rim enhancement (hazard ratio [HR] = 3.15; 95% confidence interval [CI] = 1.01, 9.88; p = .048), and lymphovascular invasion (HR = 2.73, 95% CI = 1.20, 6.23; p = .016) were independently associated with disease recurrence. While fibroglandular volume, background parenchymal enhancement, intratumoral T2 high signal, and high-signal rim on DWI, were not found to be risk factors for recurrence. CONCLUSION: Pretreatment MRI features may help predict a high risk of recurrence in patients with TNBC.